Movement Alert｜Sino Biopharmaceutical Falls 3.17% in Regular Trading, Pharmaceutical Sector Retreats Again Amid Persistent High Short-Selling Ratio

Market Focus06-25

On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.

On the news front, the pharmaceutical sector experienced another broad-based pullback, with peers CSPC Pharmaceutical down 2.5%, Asymchem down 2.04%, and Hutchmed down 1.48%. The stock's short-selling ratio remains elevated at 24.21%, reflecting strong bearish positioning. Morgan Stanley previously lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.

Despite the company announcing a share repurchase plan of up to HK$2 billion over the next 12 months and recent dual-pipeline catalysts including NMPA approval of Peceleganan Spray for burn wound infections, the stock resumed its decline after a brief two-day rebound. The 52-week low has been tested near HK$4.37, underscoring significant market divergence between fundamental developments and price action amid continued sector-wide valuation compression.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155018350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155018350","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Falls 3.17% in Regular Trading, Pharmaceutical Sector Retreats Again Amid Persistent High Short-Selling Ratio","media":"Market Focus","content":"<p><p>On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.</p><p>On the news front, the pharmaceutical sector experienced another broad-based pullback, with peers CSPC Pharmaceutical down 2.5%, Asymchem down 2.04%, and Hutchmed down 1.48%. The stock's short-selling ratio remains elevated at 24.21%, reflecting strong bearish positioning. Morgan Stanley previously lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.</p><p>Despite the company announcing a share repurchase plan of up to HK$2 billion over the next 12 months and recent dual-pipeline catalysts including NMPA approval of Peceleganan Spray for burn wound infections, the stock resumed its decline after a brief two-day rebound. The 52-week low has been tested near HK$4.37, underscoring significant market divergence between fundamental developments and price action amid continued sector-wide valuation compression.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Falls 3.17% in Regular Trading, Pharmaceutical Sector Retreats Again Amid Persistent High Short-Selling Ratio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Falls 3.17% in Regular Trading, Pharmaceutical Sector Retreats Again Amid Persistent High Short-Selling Ratio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.</p><p>On the news front, the pharmaceutical sector experienced another broad-based pullback, with peers CSPC Pharmaceutical down 2.5%, Asymchem down 2.04%, and Hutchmed down 1.48%. The stock's short-selling ratio remains elevated at 24.21%, reflecting strong bearish positioning. Morgan Stanley previously lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.</p><p>Despite the company announcing a share repurchase plan of up to HK$2 billion over the next 12 months and recent dual-pipeline catalysts including NMPA approval of Peceleganan Spray for burn wound infections, the stock resumed its decline after a brief two-day rebound. The 52-week low has been tested near HK$4.37, underscoring significant market divergence between fundamental developments and price action amid continued sector-wide valuation compression.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1155018350","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155018350","pubTimestamp":1782352731,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.On the news front, the pharmaceutical sector experienced another...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"动静快讯|中国生物制药常规交易跌3.17%沽空比率持续高位医药板块再度回撤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.On the news front, the pharmaceutical sector experienced another broad-based pullback, with peers CSPC Pharmaceutical down 2.5%, Asymchem down 2.04%, and Hutchmed down 1.48%. The stock's short-selling ratio remains elevated at 24.21%, reflecting strong bearish positioning. Morgan Stanley previously lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.Despite the company announcing a share repurchase plan of up to HK$2 billion over the next 12 months and recent dual-pipeline catalysts including NMPA approval of Peceleganan Spray for burn wound infections, the stock resumed its decline after a brief two-day rebound. The 52-week low has been tested near HK$4.37, underscoring significant market divergence between fundamental developments and price action amid continued sector-wide valuation compression.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155018350","isCrawlerRequest":true}